Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
Cancer
DRUG: Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|DRUG: Imatinib mesylate, Cyclophosphamide (Dosing level 2)|DRUG: Imatinib mesylate, Cyclophosphamide (Dosing level 3)|PROCEDURE: Blood sampling
For safety: NCI-CTCAE scale version 3.0, 42 days
For anti tumoral efficiency : RECIST criteria, 70 days
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).